TMCnet News
INSYS Therapeutics Announces Participation at FDA Advisory Committee Meeting Addressing the Co-Prescribing of NaloxonePHOENIX, Dec. 18, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced that Dr. Dean Mariano, senior director, clinical development and medical affairs at INSYS, presented during the first day of the U.S. Food and Drug Administration’s (FDA) Joint Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee meeting being held Dec. 17 and 18, 2018. In his presentation, Dr. Mariano discussed the importance of co-prescribing naloxone to chronic use opioid patients; a position supported by data from a recent study conducted in which co-prescriptions resulted in fewer overdoses and fewer hospitalizations. Dr. Mariano’s remarks noted that co-prescribing naloxone may have a positive impact on unintentional opioid overdose deaths. However, it is difficult to predict who on chronic opioid therapy will experience an overdose. Therefore, if naloxone is co-prescribed in a Universal Precautions manner for all patients receiving chronic opioid therapy, it may have a significant impact on unintentional opioid overdose deaths. “Given the ongoing opioid crisis in the United States, the FDA Advisory Committee meeting on the necessity of co-prescribing naloxone and opioids is an important step in understanding how to curb accidental overdoses in chronic use patients,” said Dr. Ahmed Elkashef, vice president of clinical development at INSYS Therapeutics. “We were privileged to participate in this critical discussion and look forward toproviding additional insights on how to best serve and protect these patients in the future.” An archive containing meeting materials, including slides, a transcript, and webcast replay of the meeting, which was held at the FDA White Oak Campus in Silver Spring, Maryland, can be found on the FDA website. About INSYS Forward-Looking Statements
|